Cited by 216Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Watanabe, Masaru, Kawaguchi, Tomoya, Isa, Shun-ichi, Ando, Masahiko, Tamiya, Akihiro, Kubo, Akihito, Saka, Hideo, Takeo, Sadanori, Adachi, Hirofumi, Tagawa, Tsutomu, Kakegawa, Seiichi, Yamashita, Motohiro, Kataoka, Kazuhiko, Ichinose, Yukito, Takeuchi, Yukiyasu, Sakamoto, Kazuhiro, Matsumura, Akihide, Koh, Yasuhiro·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-2151

Published version of a preprint

Open this paper in CoChat — free account

Abstract

PURPOSE: The resistance to the EGFR tyrosine kinase inhibitors (TKI) is a major concern in non-small cell lung cancer (NSCLC) treatment. T790M mutation in EGFR accounts for nearly 50% of the acquired resistance to EGFR-TKIs. Earlier studies suggested that T790M mutation was also detected in TKI-naïve NSCLCs in a small cohort. Here, we use an ultra-sensitive droplet digital PCR (ddPCR) technique to address the incidence and clinical significance of pretreatment T790M in a larger cohort. EXPERIMENTAL DESIGN: ddPCR was established as follows: wild-type or T790M mutation-containing DNA fragments were cloned into plasmids. Candidate threshold was identified using wild-type plasmid, normal human genomic DNA, and human A549 cell line DNA, which expresses wild type. Surgically resected tumor tissues from 373 NSCLC patients with EGFR-activating mutations were then examined for the presence of T790M using ddPCR. RESULTS: Our data revealed a linear performance for this ddPCR method (R(2) = 0.998) with an analytical sensitivity of approximately 0.001%. The overall incidence of the pretreatment T790M mutation was 79.9% (298/373), and the frequency ranged from 0.009% to 26.9%. The T790M mutation was detected more frequently in patients with a larger tumor size (P = 0.019) and those with common EGFR-activating mutations (P = 0.022), as compared with the others. CONCLUSIONS: The ultra-sensitive ddPCR assay revealed that pretreatment T790M was found in the majority of NSCLC patients with EGFR-activating mutations. ddPCR should be utilized for detailed assessment of the impact of the low frequency pretreatment T790M mutation on treatment with EGFR-TKIs.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2151

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Self-citation
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373

Show all 42 references

Sorted by citations

Items 101–200 of 216

Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR
Wang, L., Guo, Q., Yu, W., Qiao, L., Zhao, M., Zhang, C., Hu, X., Yang, G., Xiong, L., & Lou, J. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.10.007 · Cited by 24
Liquid Biopsy and Their Application Progress in Head and Neck Cancer: Focus on Biomarkers Ctcs, Cfdna, Ctdna and Evs
Meng, Y., Bian, L., Zhang, M., Bo, F., Lu, X., & Li, D. (2020) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0022 · Cited by 24
Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance
Ni, J., Weng, L., Liu, Y., Sun, Z., Bai, C., & Wang, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6022 · Cited by 23
Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study)
Akamatsu, H., Koh, Y., Okamoto, I., Fujimoto, D., Bessho, A., Azuma, K., Morita, S., Yamamoto, N., & Nakagawa, K. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.021 · Cited by 23
Digital Nucleic Acid Signal Amplification Platform for Highly Sensitive DNA Mutation Analysis
Wu, H., Ma, X., Chu, Y., Qi, X., Zou, B., Liu, Y., & Zhou, G. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04765 · Cited by 23
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
Tokudome, N., Koh, Y., Akamatsu, H., Fujimoto, D., Okamoto, I., Nakagawa, K., Hida, T., Imamura, F., Morita, S., & Yamamoto, N. (2020) · BMC Cancer · doi:10.1186/s12885-020-6593-1 · Cited by 23
Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation
Sun, Q., Liu, Y., Liu, B., & Liu, Y. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.09.009 · Cited by 22
A direct and multiplex digital PCR chip for EGFR mutation
Yin, J., Xia, L., Zou, Z., Zhuang, J., & Mu, Y. (2022) · Talanta · doi:10.1016/j.talanta.2022.123725 · Cited by 22
Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance
He, J., Tan, W., Tang, X., & Ma, J. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0097-y · Cited by 23
Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis
Jia, J., Huang, B., Zhuang, Z., & Chen, S. (2018) · The International Journal of Biological Markers · doi:10.1177/1724600817753576 · Cited by 23
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
Zhu, Y.-J., Zhang, H.-B., Liu, Y., Zhang, F., Zhu, Y., Li, Y., Bai, J., Liu, L., Qu, Y., Qu, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14490 · Cited by 21
Robust Multiplexed Clustering and Denoising of Digital PCR Assays by Data Gridding
Lau, B. T., Wood-Bouwens, C. M., & Ji, H. P. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02688 · Cited by 21
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
Beau‐Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J., Bringuier, P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.013 · Cited by 21
Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
Lei, L., Wang, W., Zhu, Y., Li, J., Fang, Y., Wang, H., Zhuang, W., Zhang, Y.-B., Wang, L., Fang, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14277 · Cited by 20
Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Rosell, R., & Karachaliou, N. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3458 · Cited by 20
Ultrasensitive Nucleic Acid Testing: From Foundational Research to Clinical Translation
Li, B., Gu, X., Zeng, W., Lin, B., Liu, X., Lim, C. T., & Liu, P. (2025) · ACS Nano · doi:10.1021/acsnano.5c15324 · Cited by 20
Multiplex and on-site PCR detection of swine diseases based on the microfluidic chip system
Jiang, Y., Jiang, S., Wu, Y., Zhou, B., Wang, K., Jiang, L., Long, Y.-F., Chen, G., & Zeng, D. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02825-w · Cited by 19
Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice
Su, K., Kao, J., Ho, B., Chen, H., Chang, G.-C., Ho, C., & Yu, S. (2016) · Scientific Reports · doi:10.1038/srep30944 · Cited by 19
Circulating Tumor Cells in Patients with Lung Cancer: Developments and Applications for Precision Medicine
Tong, B., & Wang, M. (2019) · Future Oncology · doi:10.2217/fon-2018-0548 · Cited by 18
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
Watanabe, M., Kawaguchi, T., Isa, S., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.06.003 · Cited by 18
ATP1A3 mosaicism in families with alternating hemiplegia of childhood
Yang, X., Yang, X., Chen, J., Li, S., Zeng, Q., Huang, A. Y., Ye, A. Y., Yu, Z., Wang, S., Jiang, Y., et al. (2019) · Clinical Genetics · doi:10.1111/cge.13539 · Cited by 19
Bead-Based Multiplexed Droplet Digital Polymerase Chain Reaction in a Single Tube Using Universal Sequences: An Ultrasensitive, Cross-Reaction-Free, and High-Throughput Strategy
Gu, Z., Sun, T., Guo, Q., Wang, Y., Ge, Y., Gu, H., Xu, G., & Xu, H. Y. (2022) · ACS Sensors · doi:10.1021/acssensors.2c01415 · Cited by 17
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
Molina‐Vila, M. Á., Stahel, R. A., Dafni, U. G., Jordana‐Ariza, N., Balada‐Bel, A., Garzón‐Ibáñez, M., García‐Peláez, B., Mayo‐de‐las‐Casas, C., Felip, E., Fontecedro, A. C., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.11.023 · Cited by 18
Detection of the EGFR G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR
Esteva-Socias, M., Enver-Sumaya, M., Bellvert, C. G., Guillot, M., Azkárate, A., Marsé, R., Sastre, Ú., Blasco, A., Fariñas, S. C., Asensio, V. J., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.594900 · Cited by 17
A digital PCR assay development to detect EGFR T790M mutation in NSCLC patients
Zhou, R., Cai, Y., Li, Z., Shen, S., Sha, M., Head, S. R., & Wang, Y. (2018) · Frontiers in Laboratory Medicine · doi:10.1016/j.flm.2018.08.002 · Cited by 17
Recent advances in targeted advanced lung cancer therapy in the elderly
Losanno, T., & Gridelli, C. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1348232 · Cited by 16
Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
Liu, B., Duenas, D., Zheng, L., Reckamp, K. L., & Shen, B. (2021) · Protein & Cell · doi:10.1007/s13238-021-00855-6 · Cited by 17
A Rapid Digital PCR System with a Pressurized Thermal Cycler
Chen, X., Song, Q., Zhang, B., Gao, Y., Lou, K., Liu, Y., & Wen, W. (2021) · Micromachines · doi:10.3390/mi12121562 · Cited by 16
The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR
Tatematsu, T., Okuda, K., Suzuki, A., Oda, R., Sakane, T., Kawano, O., Haneda, H., Moriyama, S., Sasaki, H., & Nakanishi, R. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.07.02 · Cited by 16
EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts
Lavdovskaia, E. D., Iyevleva, A. G., Соколенко, А. П., Mitiushkina, N. V., Преображенская, Е. В., Tiurin, V. I., Ivantsov, A. O., Валерьевич, Б. И., Stelmakh, L. V., Moiseenko, F. V., et al. (2018) · Oncology Research and Treatment · doi:10.1159/000491441 · Cited by 17
Detection of EGFR mutation of pulmonary adenocarcinoma in sputum using droplet digital PCR
Isaka, T., Yokose, T., Ito, H., Nakayama, H., Miyagi, Y., Saito, H., & Masuda, M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01468-9 · Cited by 15
Stratified Treatment in Lung Cancer
Michels, S. Y. F., & Wolf, J. (2016) · Oncology Research and Treatment · doi:10.1159/000453406 · Cited by 15
Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges
Xia, B., Zhang, S., & Ma, S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.67 · Cited by 15
“SMART” digital nucleic acid amplification technologies for lung cancer monitoring from early to advanced stages
Ren, Y., Cao, L., You, M., Ji, J., Gong, Y. M., Ren, H., Xu, F., Guo, H., Hu, J., & Li, Z. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116774 · Cited by 14
A density-watershed algorithm (DWA) method for robust, accurate and automatic classification of dual-fluorescence and four-cluster droplet digital PCR data
Zhu, X., Su, S., Fu, M., Peng, Z., Wang, D., Rui, X., Wang, F., Liu, X., Liu, B., Zhu, L., et al. (2019) · The Analyst · doi:10.1039/c9an00637k · Cited by 14
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
Matsumoto, Y., Sawa, K., Fukui, M., Oyanagi, J., Yoshimoto, N., Suzumura, T., Watanabe, T., Kaneda, H., Mitsuoka, S., Asai, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.029 · Cited by 13
Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer
Wang, X., Li, X., Guo, H., Zhu, L., Peng, Z., Wang, J., Yang, F., & Guo, Y. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s267677 · Cited by 13
A visual method for determination of hepatitis C virus RNAs based on a 3D nanocomposite prepared from graphene quantum dots
Li, Y., Li, J., Cao, Y., Jiang, P., Tang, Y., Chen, Z., & Han, K. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339693 · Cited by 13
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
Köhler, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00009 · Cited by 13
Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
Zhou, Y., Ma, Y., Shi, H., Du, Y., & Huang, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-33816-x · Cited by 13
Branch migration based selective PCR for DNA mutation enrichment and detection
Chen, N., Ouyang, X., Lin, M., Liu, N., Wu, T., & Xiao, X. (2019) · Chemical Communications · doi:10.1039/c9cc04161c · Cited by 12
Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
Lee, S. H., Kim, E. Y., Kim, A., & Chang, Y. S. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1776579 · Cited by 11
Highly Sensitive Detection of T790 M with a Three-Level Characteristic Current by Thymine–Hg(II)–Thymine in the α-Hemolysin Nanopore
Li, Y., Yang, Y., Zhong, C., Xiao, D., & Zhou, C. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05571 · Cited by 11
Low-level parental mosaicism affects the recurrence risk of holoprosencephaly
Hu, P., Martinez, A. F., Kruszka, P., Berger, S. I., Roessler, E., & Muenke, M. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0261-8 · Cited by 12
Early Monitoring Drug Resistant Mutation T790M with a Two-Dimensional Simultaneous Discrimination Nanopore Strategy
Lei, J., Huang, Y., Zhong, W., Xiao, D., & Zhou, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00575 · Cited by 11
Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations
Otsuji, K., Sasaki, T., Tanabe, M., & Seto, Y. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01109-8 · Cited by 12
[Progress in digital PCR technology and application].
Lin, J., Su, G., Su, W., & Zhou, C. (2017) · PubMed · doi:10.13345/j.cjb.160269 · Cited by 11
Single-Cell Analysis of circRNA Using ddPCR
Peng, J., Li, F., Xu, X., & Hu, S. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3323-6_13 · Cited by 10
Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes
Ye, L., Ardakani, N. M., Thomas, C., Spilsbury, K., Leslie, C., Amanuel, B., & Millward, M. (2020) · Pathology & Oncology Research · doi:10.1007/s12253-020-00833-z · Cited by 10
Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients
Tang, C., Zhu, L., Zhang, L., Tan, C., Peng, Z., Liu, B., Liu, W., Hu, H., Bai, Y., Wang, W., et al. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.07.003 · Cited by 10
Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans
Oh, E., Jeong, H. M., Kwon, M. J., Ha, S. Y., Park, H. K., Song, J., Kim, Y. J., Choi, J., Lee, E. H., Lee, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185826 · Cited by 10
Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients
Watanabe, F., Suzuki, K., Tamaki, S., Abe, I., Endo, Y., Takayama, Y., Ishikawa, H., Kakizawa, N., Saito, M., Futsuhara, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00060-9 · Cited by 10
Dynamic monitoring serum tumor markers to predict molecular features of EGFR ‐mutated lung cancer during targeted therapy
Chen, Z., Liu, L., Zhu, F., Cai, X., Zhao, Y., Liang, P., Ou, L., Zhong, R., Yu, Z., Li, C., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4676 · Cited by 10
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
Remón, J., & Besse, B. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000081 · Cited by 9
Tumor-educated platelets in lung cancer
Hussain, M. S., Moglad, E. H. O., Goyal, A., Rekha, M. M., Sharma, G. C., Jayabalan, K., Sahoo, S., Devi, A., Goyal, K., Gupta, G., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120307 · Cited by 9
Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms
Lee, E., Lee, K. J., Park, H., Chung, J. Y., Lee, M.-N., Chang, M. H., Yoo, J., Lee, H., Kong, S., & Eom, H. (2017) · Annals of Laboratory Medicine · doi:10.3343/alm.2018.38.2.147 · Cited by 9
Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs
Dong, Y., Zhou, Z. X., Wang, J., Ma, L., Liu, Z., Wang, Y., Song, J., Zhang, S., & Che, N. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.01.045 · Cited by 8
Single-copy detection of somatic variants from solid and liquid biopsy
Silva, A.-L., Powalowska, P. K., Stolarek-Januszkiewicz, M., Gray, E. R., Palmer, R. N., Herman, B., Frayling, C. A., & Balmforth, B. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-85545-3 · Cited by 8
A new primer construction technique that effectively increases amplification of rare mutant templates in samples
Huang, J.-K., Ling, F., Wang, T., & Wu, P. (2019) · BMC Biotechnology · doi:10.1186/s12896-019-0555-1 · Cited by 8
Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs
Tang, Y., Che, N., Yu, Y., Gao, Y., Shi, H., Feng, Q. F., Wei, B., Ma, L., Gao, M., Ma, J., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03065-0 · Cited by 8
Quantitative assessment of low-level parental mosaicism of SNVs and CNVs in Waardenburg syndrome
Li, X., Huang, S., Wang, G., Kang, D., Han, M., Wu, X., Yang, J., Zheng, Q., Zhao, C., Yuan, Y., et al. (2022) · Human Genetics · doi:10.1007/s00439-022-02517-x · Cited by 7
Robust Double Emulsions for Multicolor Fluorescence-Activated Cell Sorting
Ding, Y., Zoppi, G., Antonini, G., Geiger, R., & deMello, A. J. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c02363 · Cited by 7
The steady progress of targeted therapies, promising advances for lung cancer
Bombardelli, L., & Berns, A. J. M. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.638 · Cited by 8
Development of the Droplet Digital PCR Method for the Detection and Quantification of Erwinia pyrifoliae
He, L., Kim, S. H., & Yu, J. M. (2023) · The Plant Pathology Journal · doi:10.5423/ppj.nt.08.2022.0117 · Cited by 7
DNMT3A governs tyrosine kinase inhibitors responses through IAPs and in a cell senescence-dependent manner in non-small cell lung cancer.
Deng, Q., Li, C., Liu, J., Ji, X., Wan, X., Wang, C., Sun, H., Fang, Q., Gu, W.-Q., Ma, C., et al. (2023) · PubMed Central · Cited by 7
Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
Simarro, J., Pérez-Simó, G., Mancheño, N., Ansótegui, E., Muñoz-Núñez, C. F., Gómez‐Codina, J., Juan, Ó., & Palanca, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158526 · Cited by 6
Detecting and Quantitating Low Fraction DNA Variants with Low-Depth SequencingPreprint
Song, P., Chen, S. X., Yan, Y. H., Pinto, A., Cheng, L. Y., Dai, P., Patel, A. A., & Zhang, D. Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.26.061747 · Cited by 5
Comparative analysis of QS3D versus droplet digital PCR for quantitative measures of EGFR T790M mutation from identical plasma
Guo, Q., Wang, L., Liang, X., Zhao, M., Huang, X., Xu, W., Lou, J., & Qiao, L. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11339 · Cited by 4
Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
Yang, Z., Li, J., Hu, Y., Chen, M., Peng, D., Zong, D., Shang, Q., Tao, L., Zhao, Y., Ni, Y., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00682-0 · Cited by 4
Molecular exploration of paediatric intracranial germinomas from multi-ethnic Singapore
Low, S. Y. Y., He, C., Zou, R., Ng, L. P., Kuick, C. H., Sulaiman, N. B. S., Chang, K. T. E., Low, D. C. Y., Zhou, L., & Seow, W. T. (2020) · BMC Neurology · doi:10.1186/s12883-020-01981-0 · Cited by 4
Development of an Automated, Non-Enzymatic Nucleic Acid Amplification Test
Zimmers, Z. A., Boyd, A. D., Stepp, H. E., Adams, N. M., & Haselton, F. R. (2021) · Micromachines · doi:10.3390/mi12101204 · Cited by 4
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
Masuda, T., Miura, S., Sato, Y., TACHIHARA, M. Y., Bessho, A., Nakamura, A., Miyawaki, T., Yoshimine, K., Mori, M., Shiraishi, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45337-3 · Cited by 6
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation
Akamatsu, H., Ozawa, Y., Oyanagi, J., Fujimoto, D., Hata, A., Katakami, N., Tomii, K., Murakami, E., Sugimoto, T., Shimokawa, T., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.14844 · Cited by 4
Digital detection of T790M—yes or no to an ultrasensitive assay
Wang, W., Karampini, E., Correia, L. L., & McCaughan, F. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.05.01 · Cited by 3
Detection of Very Low-Level Somatic Mosaic COL4A5 Splicing Variant in Asymptomatic Female Using Droplet Digital PCR
Deng, H., Zhang, Y., Ding, J., & Wang, F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.847056 · Cited by 3
Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation
Mitsudomi, T. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30134-0 · Cited by 3
Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?
Suda, K. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.05.21 · Cited by 2
High-throughput and uniform large field-of-view multichannel fluorescence microscopy with super-thin dichroism for a dPCR gene chip
Otuboah, F. Y., Zheng, J., Cheng, C., Wang, Z., Wan, X., & Sun, L. (2020) · Applied Optics · doi:10.1364/ao.403495 · Cited by 3
Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies
Venkataram, R., Arjuna, S., Hosmane, G. B., & Chakraborty, A. (2021) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2021.1748 · Cited by 3
Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells
Kim, S.-J., Park, A. K., & Cho, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.06.065 · Cited by 3
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer
Weng, C.-F., Chen, P.-J., Tseng, A. H., Huang, S., & Lee, H. H. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1688-3 · Cited by 3
Case report: sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients
Wang, R., Sheng, Y., Yu, L., Zhao, J., Jiao, S., Wang, Q., & Wu, Y. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2728 · Cited by 2
The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
Li, W., Kok, K., Tan, G. W., Meng, P., Mastik, M. F., Rifaela, N., Scherpen, F. J. G., Hiltermann, T. J. N., Groen, H. J. M., van der Wekken, A. J., et al. (2022) · Cancers · doi:10.3390/cancers14143511 · Cited by 2
Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment
Tan, L., & Solomon, B. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.08.004 · Cited by 2
Resistance to Anti-Cancer Therapeutics
Woyach, J. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-23637-3_5 · Cited by 2
Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
Matsumoto, Y., Kawaguchi, T., Watanabe, M., Isa, S., Ando, M., Tamiya, A., Kubo, A., Kitagawa, C., Yoshimoto, N., & Koh, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09869-7 · Cited by 2
A multiple detection method for distinguishing gene mutations based on melting curves of extended quenching probes
Wang, J., Liu, Z., Tengfei, P., & Song, Z. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11856 · Cited by 2
[Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review].
Yang, X., Meng, F., & Zhong, D. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.101.04 · Cited by 2
The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
Verlicchi, A., Canale, M., Chiadini, E., Cravero, P., Urbini, M., Andrikou, K., Pasini, L., Flospergher, M., Burgio, M. A., Crinò, L., et al. (2023) · Life · doi:10.3390/life13091915 · Cited by 2
Are we ready to introduce T790M plasma analysis in the follow up of patients with NSCLC under treatment with EGFR-TKI?
Alegre, E., Martínez, D., Macías, M., & González, Á. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.11.70 · Cited by 1
An allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients
Baburaj, G., Parida, P., Udupa, K., Pai, A., Damerla, R. R., & Rao, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144447 · Cited by 1
Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M
Ogawara, D., Soda, H., Suyama, T., Yoshida, M., Harada, T., Fukuda, Y., & Mukae, H. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12538 · Cited by 1
PD-L1 expression from surgically resected lung tumors predictive of early progression in patients previously treated with targeted therapy for initially unresectable non-small cell lung cancer
Lim, J. U., Kang, H. S., Moon, M. H., Yeo, C. D., Jo, Y., Kim, T., Cho, D. G., & Kim, K. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-215 · Cited by 1
The History and Current State of EGFR-TKIs
Suda, K., & Mitsudomi, T. (2017) · Haigan · doi:10.2482/haigan.57.69 · Cited by 1
Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer
Tan, W. L., & Tan, D. S.-W. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.11.12 · Cited by 1
[Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation].
Wang, X., & Zhong, D. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.05.10 · Cited by 1
Analysis of KRAS G12 / G13 in colorectal cancer using an economical digital PCR assay that unequivocally differentiates missense and synonymous alleles
Bidshahri, R., Fakhfakh, K., McNeil, K., Won, J., Wolber, R. A., Hughesman, C. B., & Haynes, C. A. (2021) · The Canadian Journal of Chemical Engineering · doi:10.1002/cjce.24243 · Cited by 1
Amethod of Evaluation False-positive EGFR T790M Mutation Based on Deamining 5-methylcytosine
Nogami, S., YOSHIOKA, S., Hosokawa, Y., MOCHIZUKI, M., Wakamatsu, H., TERASAKI, H., & SHIMADU, M. (2022) · BUNSEKI KAGAKU · doi:10.2116/bunsekikagaku.71.59 · Cited by 1
[Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
Zhang, Y., Xu, Y., & Wang, M. (2016) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2016.11.08
EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?
Haraguchi, M., & Takahashi, K. (2018) · Respiratory disease series · doi:10.1007/978-981-10-8144-6_15

Authors: Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., Ichinose, Y., Takeuchi, Y., Sakamoto, K., Matsumura, A., & Koh, Y.
Affiliations: Wakayama Medical University (JP)
Osaka City University (JP)
NHO Kinki Chuo Chest Medical Center (JP)
Nagoya University Hospital (JP)
Aichi Medical University (JP)
National Hospital Organization (JP)
National Kyushu Medical Center (JP)
Sapporo National Hospital (JP)
Nagasaki Medical Center (JP)
Shikoku Cancer Center (JP)
Iwakuni Medical Center (JP)
National Hospital Organization Kyushu Cancer Center (JP)
Toneyama National Hospital (JP)
National Hospital Organization Yokohama Medical Center (JP)
Corresponding author: Koh, Yasuhiro
ORCID: Watanabe, Masaru
Kawaguchi, Tomoya
Ando, Masahiko
Tamiya, Akihiro
Kubo, Akihito
Saka, Hideo
Sakamoto, Kazuhiro
Koh, Yasuhiro
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-08-01
Volume: 21
Issue: 15
Pages: 3552-3560
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-2151
OpenAlex: W2006126363
Cited by: 216
References: 42
Citations by year: 2026: 1 · 2025: 4 · 2024: 3 · 2023: 9 · 2022: 24 · 2021: 19 · 2020: 22 · 2019: 30 · 2018: 19 · 2017: 47 · 2016: 32 · 2015: 6
FWCI: 27.38
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Japan Society for the Promotion of Science (25460896, 23501314)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: T790M mutation, non-small cell lung cancer, EGFR activating mutations, droplet digital PCR, EGFR tyrosine kinase inhibitors, acquired drug resistance, tumor size, analytical sensitivity
MeSH terms: Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Gene Frequency, Humans, Male, Middle Aged, Mutation, Polymerase Chain Reaction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Precision Medicine, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks